

Antitumour Imidazotetrazines. Part 31.¹ The Synthesis of Isotopically Labelled Temozolomide and a Multinuclear (¹H, ¹³C, ¹⁵N) Magnetic Resonance Investigation of Temozolomide and Mitozolomide

Richard T. Wheelhouse,^{*a} Derry E. V. Wilman,^b William Thomson^c and Malcolm F. G. Stevens^a


^a Cancer Research Campaign Experimental Cancer Chemotherapy Research Group, Cancer Research Laboratories, University of Nottingham, Nottingham NG7 2RD, UK

^b Cancer Research Campaign Centre for Cancer Therapeutics, Institute of Cancer Research, Cancer Research Campaign Laboratory, Cotswold Road, Sutton, Surrey SM2 5NG, UK

^c Aston Molecules Ltd., 10 Holt Court South, Aston Science Park, Birmingham B7 4EJ, UK

The antitumour drug temozolomide has been synthesized isotopically labelled with NMR active nuclei at a variety of sites and all its ¹³C and ¹⁵N NMR spectral resonances have been assigned. At low pH a site of protonation has been identified which accounts for the acid stability of the drug.

The antitumour imidazotetrazines temozolomide **1**² and mitozolomide **2**, are of considerable current interest and **1** is now in phase II clinical trials.³ Previously, ¹¹C-methyl-**1** and ¹⁴C(6)-**2** have been prepared;^{4,5} clinical and biochemical investigations



R = CH₃ Temozolomide **1**
R = CH₂CH₂Cl Mitozolomide **2**

have now made necessary the preparation of specifically labelled ¹⁵N and ¹³C samples of the drug **1**. These have exhibited a variety of interesting properties in their NMR spectra, not least among them the observation and identification of a site of protonation at low pH.

Results and Discussion

Synthesis of Labelled Compounds.—Economical synthesis of specifically ¹³C or ¹⁵N labelled **1** has been accomplished by variations on the standard synthesis⁶ (see Scheme 1). Labelling of N(2) of temozolomide **1**, Scheme (A), was achieved by diazotization using Na¹⁵NO₂ in a procedure adjusted so that the nitrite was not required in excess. Methyl isocyanate labelled with [¹⁵N]-**7a**, and [¹³C]-**7b** was prepared by the pyrolysis of 3-methyl-1,1-diphenylurea **6**, easily obtained from the reaction of methylamine hydrochloride (available with ¹⁵N or ¹³C label) with the chlorocarbamate **5**.⁷

¹³C Assignments for **1 and **2**.**—A combination of CPD, DEPT135, SIMPLE⁸ and COLOC⁹ experiments allowed assignment of all the drug ¹³C resonances (see Table 1). When the ¹³C NMR spectra of **1** and **2** were acquired using CF₃CO₂D as solvent some perturbation of the resonances was observed: whilst in most cases these shifts were small enough to be accounted for by the change of solvent, in the imidazole ring larger shifts were observed particularly for C(8) which were strongly suggestive of protonation.

¹⁵N NMR Interpretation.—Selected ¹⁵N NMR data for compounds **1**, **1a**, **1b**, **2** and **8** are collated in Table 2: the resonances assigned N-(1), -(2), -(3) have chemical shifts very


similar to related 1-aryl-3,3-dialkyltriazenes;¹⁰ those assigned N(5) and N(7) are typical of imidazoles.¹¹

Unambiguous assignment of the CONH₂ at -274.89 ppm was possible by acquiring with full ¹H NOE to show the signal as a negative triplet; N(2) and N(3) were uniquely identified by isotopic labelling. Distinguishing between the resonances of N(5) and N(7) was less straightforward: ¹H-¹⁵N HMBSC showed equivalent connections to H(6); also, the length of synthesis and the equivalence of four nitrogen atoms in the starting material¹² meant specific labelling of imidazole **3** was impractical. Carboxylic acid **8** showed negligible chemical-shift differences relative to **1** except for the signal at -101.43 ppm which shifted 4 ppm downfield which implies that this is N(7), closest to the structural alteration.

Of particular interest are the ¹⁵N spectra of imidazotetrazines **1** and **2** acquired in CF₃CO₂H solution. For **1**, the signal at -105.64 ppm in Me₂SO was considerably shifted to -168.14. Furthermore, when the data were acquired with full ¹H NOE the signal became negative, showing a proton attached to that nitrogen atom. The cation thus formed must be **9** since protonation at N(5) would disrupt the aromaticity of both rings. This provides further evidence for the assignment of N(7) and N(5). Cation **9** also accounts for the resistance of imidazotetrazinones to acid hydrolysis.¹

The ¹⁵N nucleus is relatively insensitive to electronic effects away from its immediate environment^{13,14} and attempts have been made to correlate ¹⁵N chemical shifts with partial atomic charges, for a discussion see ref. 13. Fig. 1 shows that for **1** there is indeed quite a good correlation between chemical shift and partial atomic charge (theoretical Lowdin charges for the nitrogen atoms of **1** calculated¹⁵ using the molecular mechanics package AMBER).

¹³C-¹⁵N Coupling Constants.—The preparation of ¹⁵N-labelled compounds affords the direct observation of N-X couplings in the spectra of the X-nuclei. Fig. 2 illustrates the newly measured ¹³C-¹⁵N couplings found in the current work. The 1-bond couplings are broadly illustrative of the dependence of the magnitude of the coupling constant on the hybridization of the atoms involved in the bond (Fermi contact mechanism) although effects due to resonance increase the coupling to adjacent carbonyl carbons.^{11,13,14} This is most marked in methyl isocyanate **7a** which has ¹J_{CN} of 47.8 Hz, an anomalously large coupling only exceeded by 2,4,6-trimethylbenzoxirone¹⁶ with ¹J_{CN} of 77.5 Hz, which indicates significant triple-bond character in the C-N bond.



Scheme 1 Reagents and conditions: i, $\text{Na}^{15}\text{NO}_2$, HCl , $0\text{--}5^\circ\text{C}$; ii, CH_3NCO , Me_2SO , room temp.; iii, $(^*)\text{CH}_3\text{--NH}_2\text{--HCl}$, NaOH , $\text{H}_2\text{O--EtOAc}$; iv, heat to 240°C ; v, $[\text{C}^{14}\text{N}]\text{--4}$, Me_2SO

Table 1 ^{13}C Chemical-shift data (δ) for compounds 1 and 2


Compound	Solvent	C-4	C-6	C-8	C-8a	CH_3	CH_2N	CH_2Cl	CONH_2
1	A	140.0	129.2	131.4	135.4	36.9	—	—	162.3
1	B	138.5	130.9	125.3	136.1	38.5	—	—	162.3
2	A	139.3	129.3	131.7	134.2	—	50.3*	41.6†	161.5
2	B	139.4	131.9	127.7	136.3	—	53.3	41.6	163.6

Solvents: A, $(\text{CD}_3)_2\text{SO}$ at 310 K; B, $\text{CF}_3\text{CO}_2\text{D}$ at 310 K. * δ_{H} 4.67; † δ_{H} 4.03.

Table 2 ^{15}N Chemical-shift data (δ) of imidazotetrazinones

Compound	Solvent	N-1	N-2	N-3	N-5	N-7	CONH_2
1	A	-33.99	20.02	-180.44	-199.82	-105.64	-274.89
1a	A	-32.55	20.12				(-ve t)
		[trace]					
1b	A			-180.30			
1*	B	-45.81	40.62	-174.50	-199.52	-168.14	-271.79
						(-ve s)	(-ve t)
2†	A	-31.88	18.19	-175.62	-200.38	-105.14	-274.22
2*	B	-42.65	36.49	-170.92	-200.09	-155.56	-271.90
8‡	A	-33.98	22.35	-197.10	-199.73	-101.43	

Solvents: A, Me_2SO at 305 K; B, $\text{CF}_3\text{CO}_2\text{H}$ at 305 K. () effect of acquiring with full ^1H NOE. * Assigned by analogy with 1 in Me_2SO , note the protonation of N-7. † Assigned by analogy with 1. ‡ Assigned by analogy with 1, note the shift of N-7 relative to 1 and absence of CONH_2 .



The $^2J_{\text{NC}}$ and $^3J_{\text{NC}}$ values measured in 1a and 1b show a combination of effects: the presence of a lone pair of electrons on the ^{15}N atom increases the coupling to carbon atoms close in space to the lone pair [$^2J_{\text{N}(2)\text{C}(3)}$ 7.0 Hz, whereas $^2J_{\text{N}(2)\text{C}(4)}$ 2.3 Hz]; the presence of multiple, equivalent coupling pathways [$^3J_{\text{N}(3)\text{C}(8a)}$ 7.2 Hz, whereas $^3J_{\text{N}(3)\text{C}(6)}$ 1.1 Hz and $^3J_{\text{N}(2)\text{C}(8)}$ 2.7 Hz] and conformational effects [$^3J_{\text{N}(3)\text{C}(8a)}$ 7.2 Hz whereas $^3J_{\text{N}(2)\text{C}(8)}$ 2.7 Hz]. Unusually, a 4-bond coupling, $^4J_{\text{N}(2)\text{C}(6)}$ 0.9 Hz was also resolved.

Experimental

General.—Temozolomide 1, mitozolomide 2 and 5-aminoimidazole-4-carboxamide hydrochloride 3 were obtained from




Fig. 1 Plot of ^{15}N chemical shift against the calculated Lowdin charge for the nitrogen atoms of 1

Aston Molecules Ltd, Birmingham, UK, [^{15}N]-methylamine hydrochloride (95 atom%) was purchased from Euriso-top through Fluorochem Ltd, Glossop, Derbyshire, UK and other reagents from the Aldrich Chemical Company. The carboxylic acid 8 was prepared from 1 by the method of Horspool *et al.*¹⁷




Fig. 2 ^{15}N - ^{13}C coupling constants (absolute value in Hz) observed in ^{15}N -labelled compounds

1D ^{15}N NMR spectra were recorded on a Bruker AC250 spectrometer at 25.36 MHz as previously described;¹⁰ 2D ^1H - ^{15}N HMBC on a Bruker AMX500 at 499.88 MHz. All other NMR spectra were recorded on a Bruker ARX250 spectrometer observing ^1H at 250.13 MHz and ^{13}C at 62.9 MHz. ^1H and ^{13}C chemical shifts are quoted downfield from tetramethylsilane, ^{15}N chemical shifts relative to external nitromethane. All J values are in Hz.

15N(2)-Temozolomide 1a.—A solution of compound 3 (0.429 g, 2.64 mmol) in 1 mol dm^{-3} HCl (4 cm^3) was passed through a cotton wool filter and delivered below the surface of a stirred, ice-cold solution of $\text{Na}^{15}\text{NO}_2$ (97 atom%) (0.2 g, 2.86 mmol) in water (4 cm^3), over 50 min. A heavy yellow precipitate was formed and the addition was stopped as soon as a pale pink colour persisted.⁶ The reaction mixture was stirred on ice for a further 5 min after which the solids were filtered off, washed with a small amount of cold water, ethanol and ether and then dried *in vacuo* to give 4 (0.27 g, 74%) [$\nu_{\text{max}}/\text{cm}^{-1}$ 2200s; $\delta_{\text{N}}(\text{Me}_2\text{SO})$ -27.82], which was used without further purification.

Methyl isocyanate (83 mg, 1.46 mmol) was added to a slurry of compound 4 (100 mg, 0.73 mmol) in Me_2SO (1 cm^3). After being stirred in the dark at room temperature for 36 h the mixture was diluted with ethyl acetate (10 cm^3) and the solids were filtered off and washed with a small amount of cold ethyl acetate. Compound 1a was obtained as a white solid (0.87 g, 61%), m.p. 204 °C (Found: M^+ , 195.0531. $\text{C}_6\text{H}_6\text{N}_5^{15}\text{NO}_2$ requires M , 195.0522). The absence of $(\text{M} - 1)^+$ in the mass spectrum suggests close to 100% ^{15}N incorporation.

3-[^{13}C]-Methyl-1,1-diphenylurea 6b.—Sodium hydroxide (5 g) was added over 30 min to a vigorously stirred mixture of [^{13}C]-methylamine hydrochloride (99 atom%; 4.0 g, 58.4 mmol), water (5 cm^3), diphenylcarbonyl chloride (13.54 g, 58.4 mmol) and toluene (20 cm^3). The mixture was heated at 50 °C for 40 min and then cooled for 20 min, after which the precipitate was filtered off, washed with water (5 \times 10 cm^3) and dried *in vacuo* overnight at 50 °C to yield 6b (11.98 g, 89%) (Found: C, 74.3; H, 6.1; N, 12.3. $^{12}\text{C}_5^{13}\text{CH}_6\text{N}_6\text{O}_2$ requires C, 74.42; H, 6.21; N, 12.33%; $\delta_{\text{H}}(\text{CDCl}_3)$ 7.3 (10 H, m, 2 \times Ph), 4.51 (1 H, br s, NH), 2.81 (1.5 H, d, $^1J_{\text{CH}}$ 138.1, CH_3) and 2.79 (1.5 H, d, $^1J_{\text{CH}}$ 138.1, CH_3); $\delta_{\text{C}}(\text{CDCl}_3)$ 156.7 (CO), 142.8 (quaternary aromatic C), 129.3 (CH), 127.3 (CH), 126.0 (CH) and 27.4 (s, very strong, CH_3); m/z 227 (M^+) and 169 (100) ($\text{M}-\text{CH}_3^{13}\text{CO}^+$).

[^{13}C]-Methyl Isocyanate 7b.—Urea 6b (11.75 g, 51.7 mmol) was placed in an Aldrich short path-length distillation apparatus and the receiver tubes cooled in isopropyl alcohol-solid CO_2 . The white solid was heated slowly to 250 °C using a silicone oil-bath and, over 3 h, a colourless liquid was collected (1.4 g, 69%); $\delta_{\text{H}}(\text{CDCl}_3)$ 3.02 (d, $^1J_{\text{CH}}$ 143.2, CH_3); $\delta_{\text{C}}(\text{CDCl}_3)$ 28.0 (s, CH_3) (C=O not observed).

3-[^{13}C]-Methyltemozolomide 1c.—This compound was prepared as for 1a from [^{14}N]-4 (3.94 g, 28.7 mmol) and 7b (2.5 g, 43.0 mmol) as a pale pink solid (5.23 g, 93%), m.p. 185 °C (decomp.); $\delta_{\text{H}}[(\text{CD}_3)_2\text{SO}]$ 8.83 (1 H, s, 6-H), 7.82 (1 H, br s, NH), 7.69 (1 H, br s, NH) and 3.86 (3 H, d, $^1J_{\text{CH}}$ 143.8, CH_3).

3-Methyl-1,1-diphenyl-[3- ^{15}N]-urea 6a.—This compound was prepared as for 6b from [^{15}N]-methylamine (95 atom%; 0.5 g, 7.30 mmol) as a white solid (1.48 g, 89%), m.p. 150 °C; $\delta_{\text{H}}(\text{CDCl}_3)$ 7.3 (10 H, m, 2 \times Ph), 4.48 (1 H, dq, $^1J_{\text{NH}}$ 90.0, $^3J_{\text{HH}}$ 4.7, NH, exchanged with D_2O) and 2.81 (3 H, dd, $^2J_{\text{NH}}$ 1.0, $^3J_{\text{HH}}$ 4.8, became d, J 1.0 on exchanging with D_2O , CH_3); $\delta_{\text{C}}(\text{CDCl}_3)$ 156.8 (d, $^1J_{\text{CN}}$ 24.4, CO), 142.9 (Ar-C), 129.3 (CH), 127.4 (CH), 126.1 (CH) and 27.4 (d, $^1J_{\text{CN}}$ 12.2, CH_3); m/z 227 (5) (M^+), 170 (12), 169 (100), 168 (40), 167 (23) and 58 (9) (Found: M^+ , 227.1072. $\text{C}_{14}\text{H}_{14}\text{N}^{15}\text{NO}$ requires M , 227.1076).

Methyl [^{15}N]-Isocyanate 7a.—The urea 6a (1.40 g, 6.16 mmol) was thermolysed as in the preparation of compound 7b to give 7a as a colourless liquid (0.13 g, 36%); $\delta_{\text{H}}[(\text{CD}_3)_2\text{SO}]$ 3.06 (d, $^2J_{\text{NH}}$ 2.9); $\delta_{\text{C}}[(\text{CD}_3)_2\text{SO}]$ 121.5 (d, $^1J_{\text{CN}}$ 47.8, C=O) and 28.1 (d, $^1J_{\text{CN}}$ 10.6, CH_3).

[3- ^{15}N]-Temozolomide 1b.—This compound was prepared as for 1a from [^{14}N]-4 (142 mg, 1.1 mmol) and 7a (60 mg, 1 mmol) but with addition of further unlabelled methyl isocyanate (2 mmol) at the end of the reaction time. The mixture was stored for a further 3 h to give 1b as a pale pink solid (127 mg, 63%), m.p. > 190 °C (decomp.); $\delta_{\text{H}}[(\text{CD}_3)_2\text{SO}]$ 8.80 (1 H, s, 6-H), 7.77 (1 H, s, NH), 7.65 (1 H, s, NH) and 3.87 (3 H, d, $^2J_{\text{NH}}$ 1.6, CH_3) (Found: M^+ , 195.0514. $\text{C}_6\text{H}_6\text{N}_5^{15}\text{NO}_2$ requires M , 195.0522). From the mass spectrum the isotopic incorporation was estimated as 86% ^{15}N (3).

Acknowledgements

This work was funded by the Cancer Research Campaign. We thank Dr. C. H. Schwalbe and Dr. B. J. Denny for allowing us to use their unpublished Lowdin charge data.

References

- Part 30, B. J. Denny, R. T. Wheelhouse, M. F. G. Stevens, L. L. H. Tsang and J. A. Slack, *Biochemistry*, 1994, **33**, 9045.
- M. F. G. Stevens, J. A. Hickman, S. P. Langdon, D. Chubb, L. Vickers, R. Stone, G. U. Baig, C. Goddard, N. W. Gibson, J. A. Slack, C. Newton, E. Lunt, C. Fizesmes and F. Lavelle, *Cancer Res.*, 1987, **47**, 5846.
- S. M. O'Reilly, E. S. Newlands, M. G. Glaser, M. Brampton, J. M. Rice-Edwards, R. D. Illingworth, P. G. Richards, C. Kennard, I. R. Colquhoun, P. Lewis and M. F. G. Stevens, *Eur. J. Cancer*, 1993, **29**, 940; E. S. Newlands, G. R. P. Blackledge, J. A. Slack, G. J. S. Rustin, D. B. Smith, N. S. A. Stuart, C. P. Quarterman, R. Hoffman, M. F. G. Stevens, M. H. Brampton and A. C. Gibson, *Br. J. Cancer*, 1992, **65**, 287.
- G. D. Brown, D. R. Turton, S. K. Luthra, P. Price, T. Jones, M. F. G. Stevens, D. R. Baghurst, D. M. P. Mingsos, S. Osman, S. L. Walters and F. Brady, *J. Labelled Compd. and Radiopharm.*, 1994, **30**, 100.
- J. A. Slack and C. Goddard, *J. Chromatog.*, 1985, **337**, 178.
- M. F. G. Stevens, J. A. Hickman, R. Stone, N. W. Gibson, G. U. Baig, E. Lunt and C. G. Newton, *J. Med. Chem.*, 1984, **27**, 196.

- 7 G. S. Shvindlerman, P. A. Sivokhin, G. V. Filotov and A. Y. Baskakov, *Chem. Abstr.*, 1969, **71**, 123770z.
- 8 P. E. Pfeffer, K. M. Valentine, F. W. Parrish, *J. Am. Chem. Soc.*, 1979, **101**, 1265.
- 9 H. Kessler, C. Griesinger, J. Zarbock and H. R. Loosli, *J. Magn. Reson.*, 1984, **57**, 331.
- 10 D. E. V. Wilman, *Magn. Reson. Chem.*, 1990, **28**, 729.
- 11 G. J. Martin, M. L. Martin, J.-P. Gouesnard, *¹⁵N-NMR Spectroscopy*, Springer-Verlag, Berlin and Heidelberg, 1981.
- 12 Y. F. Shealy, R. F. Struck, L. B. Holum and J. A. Montgomery, *J. Org. Chem.*, 1961, **26**, 2396.
- 13 G. C. Levy, R. L. Lichter, *Nitrogen-15 Nuclear Magnetic Resonance Spectroscopy*, John Wiley and Sons, New York, 1979.
- 14 J. Mason, *Multinuclear NMR*, Plenum Press, New York and London, 1987.
- 15 B. J. Denny and C. H. Schwalbe, personal communication.
- 16 M. Christil, J. P. Warren, B. L. Hawkins and J. D. Roberts, *J. Am. Chem. Soc.*, 1973, **95**, 4392.
- 17 K. R. Horspool, M. F. G. Stevens, C. G. Newton, E. Lunt, R. J. A. Walsh, B. L. Pedgrift, G. U. Baig, F. Lavelle and C. Fizammes, *J. Med. Chem.*, 1990, **33**, 1393.

Paper 4/04910A

Received 10th August 1994

Accepted 31st October 1994